Have you been failed by the anti-CGRP monoclonal antibody treatments? How long did you trial them before deciding they did not work? Brand new data presented at last month's American Headache Society meeting shows that a certain percentage of migraine patients take longer to respond to these medications than we originally thought. Does this mean we should trial them for a longer period of time before giving up?

Lindsay Weitzel, Ph.D. talks to Tim Smith, MD, headache specialist and migraine clinical trial expert about how this new data and how it affects us as a migraine community.